locally advanced esophageal squamous cell carcinoma
Conditions
Interventions
Experimental group:2 cycles of neoadjuvant therapy (including 2 doses of camrelizumab, 2 cycles of paclitaxel, and carboplatin)
Sponsors
Daqing Oilfield General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed esophageal squamous cell carcinoma; 2.Potentially curable locally advanced esophageal squamous cell carcinoma, specifically classified as cT1N1-3M0 or cT2-4aN0-3M0 (International Union for Cancer Control (UICC) version 8.0); 3.Aged over 18 years old; 4.ECOG PS score of 0 or 1; 5.Willing to accept neoadjuvant therapy with camrelizumab combined with chemotherapy; 6.Able to adhere to the follow-up.
Exclusion criteria
Exclusion criteria: 1.Poor control of underlying diseases or insufficiency of liver, blood and kidney functions, not suitable for neoadjuvant therapy; 2.Allergic to the drug in this study; 3.Difficulty in reconstruction of gastric tube after esophagectomy; 4.Known concurrent malignant tumor; 5.Serious infection; 6.There is a history of taking kaleyzumab, paclitaxel or carboplatin; 7.Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| tumor regression grading;progression-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactZhou Xiao
Daqing Oilfield General Hospital
Outcome results
None listed